Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C.
Uptake of hepatitis C (HCV) treatment in HIV-coinfected patients is not well described. Of 2356 HCV-seropositive patients, 180 (7.6%) started HCV treatment with interferon-based therapies. In multivariate Poisson-regression models, there was a 38% increase per year in the incidence of starting HCV treatment (95% CI 26 - 51%, p<0.0001); this increased from 3.9 per 1000 person-years follow-up (PYFU) before 1998 (95% CI 1.6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe.
Mocroft
Amanda
A
Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK. a.mocroft@pcps.ucl.ac.uk
Rockstroh
Jurgen
J
Soriano
Vincent
V
Kirk
Ole
O
Viard
Jean-Paul
JP
Caplinskas
Saulius
S
Gasiorowski
Jacek
J
Chiesi
Antonio
A
Phillips
Andrew N
AN
Lundgren
Jens D
JD
D000998:Antiviral Agents / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D015999:Multivariate Analysis; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011446:Prospective Studies
D000998:Antiviral Agents; D007372:Interferons